Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. (April 2023)

• Record Type: Journal Article
• Authors: Wolf, Jürgen; Garon, Edward B.; Groen, Harry J.M.; Tan, Daniel S.W.; Gilloteau, Isabelle; Le Mouhaer, Sylvie; Hampe, Marcio; Cai, Can; Chassot-Agostinho, Andrea; Reynolds, Maria; Sherif, Bintu; Heist, Rebecca S.
• Is Part Of: European journal of cancer. Volume 183(2023)
• Page Start: 98
• Page End: 108
• Publication Date: 2023-04
• Subjects: Patient-reported outcomes -- METex14-mutated -- Capmatinib -- Non-small cell lung cancer -- GEOMETRY mono-1; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2022.10.030
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Introduction: Capmatinib, a MET inhibitor, showed substantial antitumour activity with manageable side effects in patients with MET exon 14 ( MET ex14)-mutated advanced non-small cell lung cancer (aNSCLC) in the GEOMETRY mono-1 study. We report patient-reported outcomes (PROs) from this study. Methods: Enrolled treatment-naïve (1L) or pre-treated (2L + ) patients with aNSCLC with a MET ex14-skipping mutation received 400 mg capmatinib twice daily during 21-day treatment cycles. PROs were collected at baseline and every six weeks thereafter using EORTC QLQ-C30 global health status/quality of life (GHS/QoL), QLQ-LC13 symptoms, and EQ-5D-5L visual analogue scale (VAS) questionnaires. Results: As of 6 January 2020, 27/28 1L and 65/69 2L + patients had completed PROs at baseline; compliance rates remained >70%. Cough improved early, with meaningful improvements (≥10-point change from baseline) observed throughout cycles (mean change from baseline [SD] by week 7: 1L −13.0 [39.9], 2L + −8.2 [28.4]; week 43: 1L −28.2 [26.7], 2L + −10.5 [27.3]). QoL, assessed by GHS/QoL and VAS, improved by week 7 in 1L and 2L + patients, with improvements generally sustained over time. Median time to definitive deterioration (TTDD) in GHS/QoL was 16.6 months (95% CI: 9.7, not estimable [NE]) in 1L and 12.4 months (95% CI: 4.2, 19.4) in 2L + patients. Median TTDD for dyspnoea was 19.4 months (95% CI: 12.4, NE) and 22.1 months (95% CI: 9.9, NE) for 1L and 2L + patients, respectively, and NE for cough and chest pain. Conclusions: Capmatinib was associated with clinically meaningful improvements in cough and preserved QoL, further supporting its use in patients with MET ex14-mutated aNSCLC. Trial registration: ClinicalTrials.gov registry number: NCT02414139. Highlights: Capmatinib is indicated for advanced NSCLC with MET exon 14 skipping alterations. We present the analysis of the patient-reported outcomes from the GEOMETRY mono-1 trial. Patient-reported outcomes included the EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-5L. Capmatinib led to clinically meaningful improvements in cough and preserved QoL. Benefit was observed for both treatment-naïve and previously treated patients.